While targeting NINJ2 can enhance wild-type p53 expression and elicit tumor suppression in WT p53-harboring cancer cells, targeting NINJ2 in mutant p53-harboring cancer cells may enhance tumor cell growth. The gene discussed is TP53; the disease is cancer.